Atrial Fibrillation Clinical Trial
Official title:
DExmEdetomidine Sedation Versus Propofol SEDATION FOR Catheter ABLATION of Atrial Fibrillation Under a Cardiologist Supervision: A Randomized Controlled Pilot STUDY
Verified date | January 2021 |
Source | University Hospital Inselspital, Berne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Catheter ablation (CA) is an established therapeutic option for patients with symptomatic atrial fibrillation (AF). During the procedure, patients are usually sedated and analgesized, most commonly by administration of Propofol combined with opioids under the supervision of the electrophysiologist. However, due to the depressive effect of Propofol on the respiratory system, this regimen is not without risk. Dexmedetomidine is a highly selective alpha 2 agonist that demonstrates both analgesic and hypnotic properties with only weak effect on the respiratory system. The pharmacological profile of Dexmedetomidine may be advantageous for sedation during CA of AF. The aim of this randomized trial is to test this hypothesis and explore the safety and efficacy of Dexmedetomidine during CA of AF.
Status | Completed |
Enrollment | 160 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years - Informed consent as documented by signature - Catheter ablation of atrial fibrillation at the Department of Cardiology, Inselspital Bern Exclusion Criteria: - Contraindication to sedation by the electrophysiologist - Contraindications to either propofol or dexmedetomidine sedation - Contraindication for targeted controlled propofol infusion (BMI > 35) - American Society of Anesthesiologists (ASA) classification > III - Advanced heart block (second or third degree), if no pacemaker or internal cardioverter defibrillator is implanted - Arterial hypotension (mean < 80 mmHg) - Severe heart failure (LVEF = 30%) - Indication for general anaesthesia - Pregnant or breast-feeding women |
Country | Name | City | State |
---|---|---|---|
Switzerland | Department of Cardiology, University Hospital Inselspital Bern | Bern | Bern (Kanton) |
Lead Sponsor | Collaborator |
---|---|
University Hospital Inselspital, Berne |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Combined Incidence of Sedation-Emergent Adverse Events (Combined Safety Endpoint) | Number of participants with sustained bradycardia necessitating cardiac pacing
Number of participants with Hypercapnia, defined as rise of transcutaneously measured carbon dioxide levels (tcCO2) > 20mmHg Number of participants with Oxygen desaturation (<90%) necessitating assisted ventilation or further airway management in any form (including chin lift, oropharyngeal airway, bag, and mask ventilation or intubation) Number of participants with Hypotension necessitating termination of sedation or vasopressor administration Number of participants with necessity of termination or change of sedation protocol Number of participants with aborted procedure due to sedation issues |
within 24 hours after completion of procedure | |
Secondary | Incidence of Sedation-Emergent Adverse Events (Individual Safety Endpoints) | All single components of the primary endpoint | within 24 hours after completion of procedure | |
Secondary | Other complications | Number of complications not related to sedation (cardiac tamponade, stroke/transient ischemic attack, pericardial effusion necessitating therapeutic intervention, bleeding necessitating therapeutic intervention, others) [number of events] | from start until end of ablation procedure | |
Secondary | Opiod dose | Opiod dose required for analgesia [ug] | from start until end of ablation procedure | |
Secondary | Procedure duration | Total duration of the procedure [minutes] | from start until end of ablation procedure | |
Secondary | Fluoroscopy time | Duration of fluoroscopy [minutes] | from start until end of ablation procedure | |
Secondary | General sedation efficacy: occurrence and number of shiftings | General sedation efficacy assessed by the occurrence and number of shiftings of the acquired 3D map due to patient movements, necessitating remapping [number of events] | from start until end of ablation procedure | |
Secondary | Sedation depth | Depth of sedation assessed by the Modified Observer's Alertness/Sedation (MOAA/S) scale [mean score] | from start until end of ablation procedure | |
Secondary | Blood pressure | Mean systolic, diastolic and mean blood pressure during sedation and mean drop of blood pressure (pre-procedural blood pressure minus mean blood pressure during sedation) [mmHg] | from start until end of ablation procedure | |
Secondary | Heart rate | Mean heart rate during sedation and mean drop of heart rate (pre-procedural heart rate minus mean heart rate during sedation) [beats per minute] | from start until end of ablation procedure | |
Secondary | Refractory period | Effective refractory period of the atria and atrioventricular node [ms] | from start until end of ablation procedure | |
Secondary | Wenckebach point | Wenckebach point of the atrioventricular node [ms] | from start until end of ablation procedure | |
Secondary | Arrhythmia inducibility | Rate of inducibility of supraventricular arrhythmias during pacing manoeuvres (number of successful/number of attempts) [%] | from start until end of ablation procedure | |
Secondary | Patient satisfaction: Patient Satisfaction with Sedation Instrument (PSSI) [score] | Patient satisfaction as assessed by the Patient Satisfaction with Sedation Instrument (PSSI) [score] | within 24 hours after completion of procedure | |
Secondary | Cardiologist satisfaction: Clinician Satisfaction with Sedation Instrument (CSSI) [score] | Cardiologist satisfaction as assessed by the Clinician Satisfaction with Sedation Instrument (CSSI) [score] | within 24 hours after completion of procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |